{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-021176","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.443760+00:00","generated_at":"2026-05-15T08:46:30.194663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rockwell Medical Q4 2025 net sales $18.3M, gross margin 21% (up from 15%), full-year Adj. EBITDA $0.3M","bullets":["Q4 2025 net sales $18.3M (vs $24.7M Q4 2024); full-year net sales $69.3M (vs $101.5M) driven by reduced customer purchase volumes.","Q4 2025 gross margin 21% (up from 15% Q4 2024), a company record; full-year gross margin 17% in line with guidance.","Full-year 2025 net loss $5.3M (vs $0.5M loss in 2024) including $4.0M non-cash charges and $1.2M severance/facility costs.","Adjusted EBITDA Q4 2025 $1.0M; full-year $0.3M, second consecutive profitable year on that basis; cash grew to $25.0M.","2026 guidance: Adjusted EBITDA $1M–$2M, positive operating cash flow; pricing increase under extended purchase agreement through Dec 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-021176","json":"https://secwatch.observer/filing/0001628280-26-021176.json","markdown":"https://secwatch.observer/filing/0001628280-26-021176.md","text":"https://secwatch.observer/filing/0001628280-26-021176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/0001628280-26-021176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/rmti-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:46:30.194663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83cfd0f2957a2ca40bccbd5cf83b03ebe2d64d6b","claim":"ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2025 results: revenue $18.3 million, net income $ (0.6) million, EPS $ (0.01) per share.","evidence_excerpt":"EX-99.1 (EX-99.1) --- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/0001628280-26-021176-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2025"},{"label":"Revenue","value":"$18.3 million"},{"label":"Net income","value":"$ (0.6) million"},{"label":"EPS","value":"$ (0.01) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cdf3b4326f769d6cbf6702edf8588636dc76c55e","claim":"ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2025 results: revenue $69.3 million, net income $ (5.3) million, EPS $ (0.15) per share.","evidence_excerpt":"--- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth quarter 2025,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/0001628280-26-021176-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended December 31, 2025"},{"label":"Revenue","value":"$69.3 million"},{"label":"Net income","value":"$ (5.3) million"},{"label":"EPS","value":"$ (0.15) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}